Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Anna G Turkina"'
Autor:
Alexander V Lavrov, Oksana A Ustaeva, Elmira P Adilgereeva, Svetlana A Smirnikhina, Ekaterina Y Chelysheva, Oleg A Shukhov, Yuriy V Shatokhin, Sergey V Mordanov, Anna G Turkina, Sergey I Kutsev
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0182901 (2017)
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of BCR/ABL fusion gene in leukemic cells, which promotes uncontrolled cell proliferation. Up to 20% of CML patients show primary resistance or non-optimal re
Externí odkaz:
https://doaj.org/article/aebeca0cfcc84482b693b260ee7cce6c
Autor:
Alexander V. Lavrov, Ekaterina Yu. Chelysheva, Elmira P. Adilgereeva, Oleg A. Shukhov, Svetlana A. Smirnikhina, Konstantin S. Kochergin-Nikitsky, Valentina D. Yakushina, Grigory A. Tsaur, Sergey V. Mordanov, Anna G. Turkina, Sergey I. Kutsev
Publikováno v:
BMC Medical Genomics, Vol 12, Iss S2, Pp 5-13 (2019)
Abstract Background Approximately 5–20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy. Gene polymorphisms, express
Externí odkaz:
https://doaj.org/article/65b6107f1bb54961af0fe7269e7108aa
Autor:
Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksandr A. Siniaev, Aleksandr D. Kulagin, Kamil D. Kaplanov, Andrei A. Petrenko, Oksana I. Ochirova, Alina Karpova, Ekaterina Yu. Chelysheva, Anna G. Turkina, Margarita A. Gurianova, Liubov S. Al-Radi, Elena A. Gilyazitdinova, Elena K. Egorova, Yulia A. Chabaeva, Sergey M. Kulikov, Yulia V. Sveshnikova, Mikhail A. Kunst, Vasily Shuvaev, Anzhelika F. Rakhmani, Olga L. Panteleeva, Maria E. Grishunina, Olga S. Samoylova, Ekaterina Vorontsova, Daria V. Baryshnikova, Elena N. Parovichnikova
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeed11ea33a0b517984c8fbcb6a2dfc0
https://doi.org/10.1016/j.clml.2023.04.002
https://doi.org/10.1016/j.clml.2023.04.002
Autor:
Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio
Publikováno v:
Blood. 140:195-197
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::204f6e17e008df0ffcd6194ecac5a145
https://doi.org/10.1182/blood-2022-167177
https://doi.org/10.1182/blood-2022-167177
Autor:
Philipp le Coutre, Véronique Bédoucha, Delphine Rea, Dennis Dong Hwan Kim, Elza Lomaia, Michael J. Mauro, Andre Abdo, Lynette Chee, Sergey Voloshin, Dong-Wook Kim, Laura Fogliatto, Paola Aimone, Yosuke Minami, Alex Allepuz, Mario Annunziata, Jane F. Apperley, Susanne Saussele, Jorge E. Cortes, Andreas Hochhaus, Naeem Chaudhri, Carla Boquimpani, Koji Sasaki, Sara Quenet, Timothy P. Hughes, Anna G. Turkina, Valentín García-Gutiérrez
Publikováno v:
Blood
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ea953c680d4e6fe9a23516537c5aa9
https://doi.org/10.1182/blood.2020009984
https://doi.org/10.1182/blood.2020009984
Autor:
Natalia Sats, V G Savchenko, Ekaterina A. Fastova, Kravchenko Sk, Nina Drize, Oleg Shukhov, Anna G. Turkina, A U Magomedova, Natalia Petinati, Irina N. Shipounova, Elena N. Parovichnikova, E Yu Chelysheva
Publikováno v:
Bulletin of Experimental Biology and Medicine. 171:553-558
Multipotent mesenchymal stromal cells (MSC) are the key regulators of hematopoiesis. We studied changes in MSC characteristics in patients with myeloid leukemia and patients with lymphoproliferative diseases. MSC were obtained from the bone marrow of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0137c566a249c38e778c4e990d97376
https://doi.org/10.1007/s10517-021-05268-3
https://doi.org/10.1007/s10517-021-05268-3
Autor:
Ekaterina Yu. Chelysheva, Anna N. Petrova, Oleg A. Shukhov, Anastasiia V. Bykova, Irina S. Nemchenko, Margarita A. Gurianova, Nikolay N. Tsyba, Anna G. Turkina
Publikováno v:
Terapevticheskii arkhiv. 94(7)
Withdrawal syndrome (WS) a musculoskeletal pain after discontinuation of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML) has been described in the treatment-free remission (TFR) studies. The pathophysiological mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2163d6c89aa25eec4d7126de7a81f3b0
https://pubmed.ncbi.nlm.nih.gov/36286940
https://pubmed.ncbi.nlm.nih.gov/36286940
Autor:
Anna Petrova, Anna G. Turkina, Anastasiya Bykova, Oleg Shukhov, E Yu Chelysheva, Irina Nemchenko
Publikováno v:
Clinical oncohematology. 14:1-12
Aim. To study the impact of different clinical and biological factors on sustaining molecular remission after discontinuation of tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients with a stable deep molecular response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8ad592166103f13978fd7a5c2b11e11
https://doi.org/10.21320/2500-2139-2021-14-1-1-12
https://doi.org/10.21320/2500-2139-2021-14-1-1-12
Autor:
O.Yu. Vinogradova, T.A. Ageeva, V.V. Baikov, A L Melikyan, Elena V. Morozova, S.V. Gritsaev, Tatiana Mitina, Boris V. Afanasyev, K. D. Kaplanov, Alla M. Kovrigina, Yu. V. Shatokhin, A.Yu. Zaritskey, I N Subortseva, E.S. Polushkina, Anna G. Turkina, T. I. Pospelova, Vasily Shuvaev, Elza Lomaia, Valeriy G. Savchenko, Roman G. Shmakov, A B Sudarikov, Sokolova Ma, Tatyana Ionova, Irina Martynkevich
Publikováno v:
Clinical oncohematology. 14:262-298
The development of National clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms comes in response to the need to standardize the approach to diagnosis and treatment. The availability of clinical guidelines can f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8084e2baf0c0823aeed80c7d7057d872
https://doi.org/10.21320/2500-2139-2021-14-2-262-298
https://doi.org/10.21320/2500-2139-2021-14-2-262-298
Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors
Publikováno v:
Clinical oncohematology. 14:118-128
Tyrosine kinase inhibitor (TKI) therapy results in deep molecular response (MR) in 60-70 % of chronic myeloid leukemia (CML) patients. However, despite high efficacy of TKIs, many patients experience drug toxicity during the treatment. According to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ea501a59ca2b13f745699e9a970d3ed
https://doi.org/10.21320/2500-2139-2021-14-1-118-128
https://doi.org/10.21320/2500-2139-2021-14-1-118-128